Rare disease biotech Ultragenyx sets terms for $75 million IPO

Comment

Shutterstock photo

Ultragenyx Pharmaceutical, a clinical-stage biotech developing treatments for metabolic genetic diseases, announced terms for its IPO on Friday. The Novato, CA-based company plans to raise $75 million by offering 4.8 million shares at a price range of $14 to $17. At the midpoint of the proposed range, Ultragenyx Pharmaceutical would command a market value of $436 million.

Ultragenyx Pharmaceutical, which was founded in 2010, plans to list on the NASDAQ under the symbol RARE. The company initially filed confidentially on October 4, 2013. J.P. Morgan and Morgan Stanley are the joint bookrunners on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.



This article appears in: News Headlines , IPOs


More from Renaissance Capital

Subscribe






Renaissance Capital
Contributor:

Renaissance Capital

IPOs
Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com